Relapsing Multiple Sclerosis (RMS) Clinical Trial
Official title:
A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS).
The purpose of this study is to investigate the potential effects of cladribine on the pharmacokinetics of monophasic oral contraceptive microgynon® by assessment of its constituents, ethinyl estradiol (EE) and levonorgestrel (LNG).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03277261 -
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
|
Phase 3 | |
| Active, not recruiting |
NCT04130997 -
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT02921035 -
Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)
|
||
| Terminated |
NCT04878211 -
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
|
Phase 4 | |
| Completed |
NCT03745144 -
Effects of Cladribine Tablets on the PK of Microgynon®
|
Phase 1 | |
| Active, not recruiting |
NCT04667949 -
Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients
|
Phase 4 | |
| Completed |
NCT03277248 -
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
|
Phase 3 |